Search Results
Targeting Oncoembryonic Antigens ROR1 and ROR2 For Therapy Of Patients With Hairy Cell Leukemia
We will study the function of ROR1 and ROR2 on HCL cells that we have collected from 120 patients, examining whether they influence expression of genes that can promote the growth/survival of HCL cells. We have made antibodies that are highly specific for ROR1 or ROR2 that react with HCL cells, but not normal blood cells or tissues. We will determine if these antibodies can be used as naked antibodies, antibody-drug conjugates, or in chimeric receptors on T cells to specifically kill HCL cells.#ASH16 (Blog 2): Innovations in AML and Surprising Results for CML
This is the second of a series of blogs covering the 58th ASH Annual Meeting and Exposition in San Diego (#ASH16) conference over the next few days. Check back for more news from the meeting.
Alemtuzumab
Alemtuzumab is FDA approved to treat people who have chronic lymphocytic leukemia (CLL).
Bosutinib
Bosutinib is FDA approved for the treatment of
- Adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly diagnosed or resistant or intolerant to prior therapy.
- Adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
Filgrastim-sndz
Filgrastim-sndz is FDA approved as a biosimilar to US-licensed Neupogen® for the five indications for which Neupogen is approved:
- Patients with cancer receiving myelosuppressive chemotherapy;
- Patients with acute myeloid leukemia receiving induction or consolidation chemotherapy;
- Patients with cancer undergoing bone marrow transplantation;
- Patients undergoing autologous peripheral blood progenitor cell collection and therapy; and
- Patients with severe chronic neutropenia.
Hydroxyurea
Hydroxyurea is FDA approved to treat people who have chronic myelocytic leukemia and some other blood cancers, including essential thrombocythemia and polycythemia vera. Hydroxyurea may cause temporary loss of hair in some people. After treatment has ended, normal hair growth should return, although the new hair may be a slightly different color or texture.
Pirtobrutinib
Pirtobrutinib is indicated for the treatment of
Gemtuzumab ozogamicin
Gemtuzumab ozogamicin is approved for the treatment of
- Newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older
- Relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older (1.2).
Cancer Researcher Runs Alaska Half Marathon to Raise Funds for Lifesaving Treatments
Not only has Irene Ghobrial, M.D. dedicated her professional life to finding lifesaving treatments for cancer, but over the past few months she has dedicated her leisure time to training for a half marathon in Alaska, to raise funds for cancer research. Ghobrial has trained with The Leukemia & Lymphoma Society’s (LLS) Team In Training (TNT), the non-profit’s endurance training program.
Dispelling Misunderstandings About Clinical Trials
As a clinical trials specialist for The Leukemia & Lymphoma Society, I guide blood cancer patients and their families through the process of determining whether a clinical trial might be right for them. I try to clarify any misconceptions people have about what is involved so they will be in a much better place to make a decision. This blog addresses some of the most common misunderstandings. Considering a clinical trial for treatment of a blood cancer?
My Journey Through Stage IV Non-Hodgkin Lymphoma
Brittany Daniel is an actress best known for her role in the television series “Sweet Valley High” and the film, “Joe Dirt,” and a lifestyle blogger at The Sweet Life By Brittany + Cynthia Daniel. She and her husband, Adam, will participate in The Leukemia Cup Regatta in San Francisco (www.sflcr.org) on October 22.
Harnessing METTL3 inhibition in acute megakaryoblastic leukemia driven by the t(1;22) fusion involving a member of the m6A writer complex
I want to understand how the t(1;22) translocation that involves a member of the m6A writer complex drives acute megakaryoblastic leukemia (AMKL). To identify culprit genes and pathways I will use multi-omics, including RNA, eCLIP, and TimeLapse Seq and proteomics. I will dissect the RBM15-MKL specific effects of a novel METTL3 inhibitor in primary murine and human AMKL in vitro and in vivo. My ultimate goal is to cure this rare infant leukemia by harnessing METTL3 inhibition.Working with Lawmakers to Address the Unique Needs of Cancer Patients
As the coronavirus continues its spread, The Leukemia & Lymphoma Society (LLS) has a vital role to play in ensuring our government takes every step necessary to protect cancer patients. With that in mind, we’re sharing with our community what LLS has been doing to make sure the unique needs of blood cancer patients are being heard by the government at this unprecedented time.